Lymphoma

Dr Lori Leslie discusses how to assess if a patient with large B-cell lymphoma is a good candidate for CAR T-cell therapy.

Andrew Ip, MD, and Lori Leslie, MD, review clinical trial and real-world data on the efficacy and survival rates of CAR T-cell therapy in large B-cell lymphoma.

A partial clinical hold placed on the phase 1/2 TakeAim Lymphoma trial was lifted after a strategy to identify and manage rhabdomyolysis was agreed upon.

P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.

Patients with previously untreated diffuse large B-cell lymphoma may benefit from treatment with polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone, for which a supplemental biologics license application was accepted by the FDA.

Patients with relapsed/refractory B-cell malignancies who received zandelisib at 60 mg via an intermittent dosing schedule experienced a low incidence of grade 3 or higher adverse effects.

Patients with relapsed/refractory follicular lymphoma with 2 or more prior therapies experienced promising safety and remission rates following treatment with mosunetuzumab.

Findings from the phase 2 TRANSCEND-PILOT-017006 supported the use of lisocabtagene maraleucel as a second-line treatment for patients with large B-cell lymphoma who were not able to or didn’t want to receive hematopoietic stem cell transplant.

Dexamethasone, Cisplatin, gemcitabine, and pegaspargase resulted in improved preliminary outcomes vs dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide for patients with newly diagnosed locally advanced stage III or IV extranodal natural killer/ T-cell lymphoma.

WU-CART-007 was granted fast track and rare pediatric disease designation by the FDA for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

Catherine S. Diefenbach, MD, spoke about refining understanding of CAR T-cell therapies after the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma.

Patients with relapsed/refractory large B-cell lymphoma may benefit from treatment with epcoritamab, for which a biologics license application will be submitted to the FDA.

Based on results of a phase 1/2 trial of single-agent mosunetuzumab in B-cell malignancies, the agent was granted priority review by the FDA for the treatment of relapsed/refractory follicular lymphoma.

Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma who do not have chemotherapy-sensitive disease.

In the phase 2 Alliance A059102 trial, patients with treatment-naïve CD30-negative peripheral T-cell lymphoma will be treated with duvelisib and azacitidine plus CHOP/CHOEP chemotherapy.

Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for the treatment of relapsed/refractory large B-cell lymphoma following 1 prior therapy.

Punctual and kinetic minimal residual disease analysis could be a robust predictor of mantle cell lymphoma’s natural history and could represent an adaptable model for continuous patient risk assessment.

Based on results from the phase 3 TRANSFORM trial, the FDA has approved lisocabtagene maraleucel for the second-line treatment of relapsed/refractory large B-cell lymphoma.

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

The 3-year follow-up update from the phase 2 ZUMA-2 trial showed continued responses for patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.

This review article written by Meghana Kesireddy, MBBS and Matthew A. Lunning, MD, reviews management and treatment of relapsed/refractory large B-cell lymphoma.

An expansion cohort from the phase 2 EPCORE NHL-1 trial demonstrated strong efficacy of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Based on results from the phase 1/2 GO29781 trial, the European Commission has approved mosunetuzumab for adult patients with relapsed/refractory follicular lymphoma.

Treatment with zanubrutinib and obinutuzumab improved outcomes in patients with relapsed/refractory follicular lymphoma vs obinutuzumab monotherapy.

Subgroup analysis of the RE-MIND trial support use of tafasitamab plus lenalidomide to treat high-risk diffuse large B-cell lymphoma.

The phase 2 PILOT study showed encouraging overall response rates with lisacabtagene maraleucel in the second-line or beyond setting among patients with relapsed/refractory large B-cell lymphoma who did not receive hematopoietic stem cell transplantation.

Epcoritamab plus rituximab and lenalidomide yielded a 100% response rate in patients with relapsed or refractory follicular lymphoma.

High response rates were noted in a phase 1/2 trial of the bispecific antibody epcoritamab to treat first-line, high-risk diffuse large B-cell lymphoma.

Phase 2 data indicate promising responses are possible with fixed-duration glofitamab in patients with heavily pretreated, highly refractory large B-cell lymphoma.

Prior findings showing the benefit of brentuximab vedotin plus chemotherapy vs chemotherapy alone for the treatment of patients with previously untreated stage III/IV classical Hodgkin lymphoma was supported by 6-year updated overall survival data.